Nyrada Inc – Brain Injury Program GLP Studies Further Update 4

Highlights:
•Completed dog cardiovascular study provides ongoing data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate NYR-BI03.
•Study was satisfactorily completed under Good Laboratory Practice (GLP) conditions.
•Coupled with earlier hERG study, dog cardiovascular study completes the regulatory cardiac safety profiling of NYR-BI03.
•Nyrada will continue to report on remaining GLP study results and remains on track to commence first in-human Phase I clinical trial for NYR-BI03 in late CY2024.